Arrowhead Pharmaceuticals, Inc. (ARWR)

18.17
NASDAQ
Prev Close 18.17
Day Low/High 0.00 / 0.00
52 Wk Low/High 6.31 / 22.39
Exchange NASDAQ
Shares Outstanding 94.21B
Market Cap 1.71B
Div & Yield N.A. (N.A)
Arrowhead Initiates Dosing Of ARC-AAT In Patients With Alpha-1 Antitrypsin Deficiency

Arrowhead Initiates Dosing Of ARC-AAT In Patients With Alpha-1 Antitrypsin Deficiency

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it dosed the first patient in Part B of a Phase 1 clinical trial of ARC-AAT.

Today's Weak On High Volume Stock: Arrowhead Research (ARWR)

Today's Weak On High Volume Stock: Arrowhead Research (ARWR)

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a weak on high relative volume candidate

Arrowhead Research (ARWR) Stock Gains as Germany Clears Further HBV Tests

Arrowhead Research (ARWR) Stock Gains as Germany Clears Further HBV Tests

Arrowhead Research (ARWR) shares are rising after the company received regulatory approval in Germany to continue testing its hepatitis B treatment candidate.

Arrowhead Research (ARWR) Is Today's Strong On High Volume Stock

Arrowhead Research (ARWR) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a strong on high relative volume candidate

Arrowhead Receives Regulatory Clearance To Begin Additional Phase 2b Studies Of Hepatitis B Candidate ARC-520

Arrowhead Receives Regulatory Clearance To Begin Additional Phase 2b Studies Of Hepatitis B Candidate ARC-520

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that its Clinical Trial Application for ARC-520, its clinical candidate for chronic hepatitis...

Commit To Purchase Arrowhead Research Corp At $5, Earn 32% Using Options

Commit To Purchase Arrowhead Research Corp At $5, Earn 32% Using Options

Investors eyeing a purchase of Arrowhead Research Corp shares, but tentative about paying the going market price of $6.65/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2017 put at the $5 strike, which has a bid at the time of this writing of $1.60.

Arrowhead Receives Orphan Drug Designation For ARC-AAT

Arrowhead Receives Orphan Drug Designation For ARC-AAT

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the United States Food and Drug Administration (FDA) has granted ARC-AAT orphan drug...

Arrowhead To Present At Jefferies 2015 Healthcare Conference

Arrowhead To Present At Jefferies 2015 Healthcare Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Arrowhead's president and chief executive officer Christopher Anzalone, Ph.

RSI Alert: Arrowhead Research (ARWR) Now Oversold

RSI Alert: Arrowhead Research (ARWR) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Arrowhead Reports Fiscal 2015 Second Quarter Financial Results

Arrowhead Reports Fiscal 2015 Second Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2015 second quarter ended March 31, 2015.

Arrowhead Presents Data On Potential RNAi Candidate Targeting Factor 12 Mediated Angioedemic And Thromboembolic Diseases

Arrowhead Presents Data On Potential RNAi Candidate Targeting Factor 12 Mediated Angioedemic And Thromboembolic Diseases

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today presented data at IBC's 17 th Annual TIDES Conference in San Diego on the preclinical development of an...

Arrowhead Completes Dosing Healthy Volunteers And Initiates Transition To Patients In Phase 1 Study Of ARC-AAT

Arrowhead Completes Dosing Healthy Volunteers And Initiates Transition To Patients In Phase 1 Study Of ARC-AAT

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed dosing healthy volunteers and will begin dosing patients in an on-going...

Arrowhead To Report Fiscal 2015 Second Quarter Financial Results

Arrowhead To Report Fiscal 2015 Second Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2015 second quarter ended March 31,...

Arrowhead Publishes Data On Advances In Subcutaneous SiRNA Delivery

Arrowhead Publishes Data On Advances In Subcutaneous SiRNA Delivery

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the publication of new data on a subcutaneously administered formulation of its Dynamic...

Arrowhead To Present At Upcoming Conferences

Arrowhead To Present At Upcoming Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will present at the following upcoming investor and scientific conferences.

Trade-Ideas: Arrowhead Research (ARWR) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Arrowhead Research (ARWR) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a strong on high relative volume candidate

Arrowhead Research (ARWR) Stock Falls Today on Jefferies Downgrade

Arrowhead Research (ARWR) Stock Falls Today on Jefferies Downgrade

Shares of Arrowhead Research (ARWR) fell Tuesday after Jefferies downgraded the biopharmaceutical company to 'Hold' from 'Buy' and slashed its price target to $9 from $30.

Arrowhead Research (ARWR) Weak On High Volume

Arrowhead Research (ARWR) Weak On High Volume

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a weak on high relative volume candidate

Arrowhead Research (ARWR) Stock Rises Today as FDA Allows Study to Proceed

Arrowhead Research (ARWR) Stock Rises Today as FDA Allows Study to Proceed

Shares of Arrowhead Research (ARWR) were up in late morning trading Monday after the biopharmaceutical company announced a new permission from the Food and Drug Administration.

Heavy Trading On Arrowhead Research (ARWR) Before Market Open

Heavy Trading On Arrowhead Research (ARWR) Before Market Open

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a pre-market mover with heavy volume candidate

Arrowhead Cleared To Proceed With Multiple Dose Phase 2b Study Of ARC-520

Arrowhead Cleared To Proceed With Multiple Dose Phase 2b Study Of ARC-520

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the United States Food and Drug Administration (FDA) informed the Company that it can...

3 Stocks Under $10 Triggering Breakout Trades

3 Stocks Under $10 Triggering Breakout Trades

Keep these under-$10 stocks on your breakout trading radar.

Trade-Ideas: Arrowhead Research (ARWR) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Arrowhead Research (ARWR) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a weak on high relative volume candidate

First Week of ARWR September 18th Options Trading

First Week of ARWR September 18th Options Trading

Investors in Arrowhead Research Corp saw new options begin trading this week, for the September 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 193 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

Arrowhead Research (ARWR): Heavy Pre-Market Activity

Arrowhead Research (ARWR): Heavy Pre-Market Activity

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a pre-market mover with heavy volume candidate

Arrowhead Acquires Novartis' RNAi Research And Development Portfolio

Arrowhead Acquires Novartis' RNAi Research And Development Portfolio

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the acquisition of Novartis' entire RNAi research and development portfolio and associated...

Arrowhead To Present At 2015 Barclays Global Healthcare Conference

Arrowhead To Present At 2015 Barclays Global Healthcare Conference

Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Arrowhead's president and chief executive officer Christopher Anzalone, Ph.

'Mad Money' Lightning Round: Stick With Restoration Hardware

'Mad Money' Lightning Round: Stick With Restoration Hardware

Cramer says 3M is a buy, buy, buy but Encana and GoPro are not for him.

Arrowhead Begins Phase 1 Trial Of ARC-AAT For Treatment Of Liver Disease Associated With Alpha-1 Antitrypsin Deficiency

Arrowhead Begins Phase 1 Trial Of ARC-AAT For Treatment Of Liver Disease Associated With Alpha-1 Antitrypsin Deficiency

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has initiated dosing in a Phase 1 clinical trial of ARC-AAT, the company's candidate...

TheStreet Quant Rating: D (Sell)